Skip to Content
A62 / P62
NCODA Oncology and Hematology Meeting Abstracts | Volume 2 | Supplement 2
Publication Date: October 13, 2026

Efficacy and safety of ivonescimab-chemotherapy versus placebo-chemotherapy in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small cell lung cancer in the phase 3 HARMONi study

Authors:

Xiuning Le, MD1; Antonio Passaro, MD2; Janessa Laskin, MD3; Delvys Rodriguez-Abreu, MD4; Antonio Calles Blanco, MD5; Lyudmila Bazhenova, MD6; Giuseppe Lo Russo, MD7; Natasha Leighl, MD8; Federico Cappuzzo, MD9; Nicolas Girard, MD10; Sanjay Popat, MD11; Wenfeng Fang, MD12; Yongzhong Luo, BM13; Runxiang Yang, MS14; Howard West, MD15; Jianling Li, MS15; Jonathan W. Goldman, MD16; Li Zhang, MD12

Organization / Company:

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2European Institute of Oncology IRCCS, Milan, Italy; 3British Columbia Cancer and University of British Columbia, Vancouver, BC, Canada; 4Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain;5Hospital General Universitario Gregorio Marañón, Madrid, Spain; 6UC San Diego Moores Cancer Center, San Diego, CA, USA; 7Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 8UNH Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; 9Regina Elena National Cancer Institute, Rome, Italy; 10Institut Curie, Paris, France; 11Lung Unit, Royal Marsden Hospital, London, United Kingdom; 12Sun Yat-sen University Cancer Center, Guangzhou, China; 13Hunan Cancer Hospital, Changsha, China; 14The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming, China; 15Summit Therapeutics, Inc., Menlo Park, CA, USA; 16UCLA Health, Los Angeles, CA, USA

NCODA Oncol Hematol Meet Abstr. 2026;2(suppl 2):abstr 62.

Background:

Ivonescimab is a first-in-class bispecific antibody that cooperatively targets both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF).

 

Objectives:
  • Discuss the efficacy and safety of ivonescimab plus chemotherapy compared with placebo plus chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) in the phase 3 HARMONi trial.
  • Summarize intracranial efficacy outcomes from HARMONi in patients with EGFR-mutated NSCLC with and without brain metastases at baseline.

 

Purpose:

The global, randomized, double-blind, phase 3 HARMONi (NCT06396065) study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC whose disease progressed on a third-generation EGFR tyrosine kinase inhibitor (TKI).

 

Methods:

Patients were randomly assigned (1:1), stratified by the presence or absence of brain metastases and geographic region, to ivonescimab (20 mg/kg) or placebo plus pemetrexed and carboplatin every 3 weeks for 4 cycles, followed by maintenance therapy. The dual primary endpoints were progression-free survival (PFS; by independent review committee) and overall survival (OS). Exploratory endpoints were intracranial PFS and cumulative incidence probability of intracranial progression in patients with and without brain metastases at baseline.

 

Results:

A total of 438 patients were randomized (219 to each arm); 54 in each arm had brain metastases at baseline. At the primary analysis (n=345; median follow-up, 22.3 months), median PFS was 6.8 months with ivonescimab plus chemotherapy versus 4.4 months with placebo plus chemotherapy (hazard ratio [HR], 0.52 [95% confidence interval (CI), 0.41–0.66]; P<0.0001). At the final OS analysis (median follow-up, 29.7 months), median OS was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with placebo plus chemotherapy (HR, 0.79 [95% CI, 0.62–1.01]). Median intracranial PFS was 10.1 months with ivonescimab plus chemotherapy versus 6.5 months with placebo plus chemotherapy in patients with brain metastases (HR, 0.53 [95% CI, 0.33–0.84]; P=0.0068) and 15.7 versus 11.6 months in patients without brain metastases (HR, 0.72 [95% CI, 0.55–0.94]; P=0.0172). Cumulative incidence probability (95% CI) of intracranial progression was lower with ivonescimab plus chemotherapy versus placebo plus chemotherapy at 6 and 12 months for patients with brain metastases (6 months: 0.06 [0.02–0.15] versus 0.30 [0.19–0.43]; 12 months: 0.10 [0.04–0.21] versus 0.36 [0.22–0.49]; P=0.0007) and without brain metastases (6 months: 0.03 [0.01–0.06] versus 0.08 [0.05–0.13]; 12 months: 0.03 [0.01–0.07] versus 0.10 [0.06–0.15]; P=0.0136). Grade ≥3 treatment-related adverse events (TRAEs) occurred in 50.0% of patients in the ivonescimab plus chemotherapy arm versus 42.2% in the placebo plus chemotherapy arm; grade ≥3 VEGF-blocking TRAEs occurred in 7.3% versus 3.2% of patients, respectively. Frequencies of TRAEs leading to discontinuation of ivonescimab or placebo were 7.3% versus 5.0%, and frequencies of TRAEs leading to death were 1.8% versus 2.3% in the ivonescimab plus chemotherapy versus placebo plus chemotherapy arms, respectively.

 

Conclusion:

Ivonescimab plus chemotherapy showed significant PFS benefit and a manageable safety profile in patients with EGFR-mutated NSCLC after third-generation EGFR-TKI therapy. Intracranial PFS benefit and reduced risk of intracranial progression were seen in patients with and without brain metastases at baseline.

Funding: Summit Therapeutics Inc.

 

Prior Presentations:

Presented at the European Lung Cancer Congress (ELCC) 2026, Final Publication Number (FPN) 106322, Xiuning Le, et al. (reused with permission); World Conference on Lung Cancer (WCLC) 2025, September 6–9, 2025, in Barcelona, Spain; and AMCP Nexus 2026, October 26–29, 2026, in San Diego, CA, USA.

A62 / P62